

## Asymptomatic carriage of *Plasmodium falciparum* in children living a hyperendemic area occurs independently of IgG responses but is associated with induction of IL-10

### Proposed authors:

Balotin Fogang<sup>1,2</sup>, Mathieu Schoenhals<sup>1</sup>, Franklin Maloba<sup>1</sup>, Marie Florence Abite<sup>1,3</sup>, Estelle Essangui<sup>1</sup>, Christiane Donkeu<sup>1,2</sup>, Glwadys Cheteug<sup>1,4</sup>, Marie Kapen<sup>1</sup>, Rodrigue Keumoe<sup>1</sup>, Sylvie Kemleu<sup>1</sup>, Ronald Perraut<sup>1</sup>, Rosette Megnekou<sup>2</sup>, Tracey Lamb<sup>5</sup>, Lawrence Ayong\*<sup>1</sup>

### Affiliations:

<sup>1</sup> Molecular Parasitology Laboratory, Centre Pasteur du Cameroun, BP 1274 Yaounde, Cameroon,

<sup>2</sup> Department of Animal Biology and Physiology of the University of Yaoundé I, BP 812 Yaounde, Cameroon,

<sup>3</sup> Department of Biochemistry, University of Douala, BP 24157 Douala, Cameroon,

<sup>4</sup> Department of Medical Laboratory Sciences, University of Buea, BP 63 Buea, Cameroon,

<sup>5</sup> Department of Pathology, University of Utah, 15 N Medical Drive, Salt Lake City 84112, USA.

\* Correspondence to: Lawrence Ayong [layong05@yahoo.co.uk](mailto:layong05@yahoo.co.uk)

**Key words:** Asymptomatic malaria, *Plasmodium falciparum*, IgG, invasion blocking, cytokine, IL-10

### Abstract

**Background:** Malaria immuno-epidemiological data suggest that two key immunological processes, including anti-parasite and anti-disease immunity, may be implicated in the maintenance of asymptomatic infections. However, in highly exposed persons where the duration of chronic malaria infection could range from a few weeks to several years, the host immunological factors that determine the persistence of asymptomatic parasitemia remain poorly understood. This study therefore aimed to define the association between antibody or cytokine responses with asymptomatic malarial parasitemia amongst highly exposed individuals in Cameroon.

**Methods:** An initial cross-sectional study was carried out (week 1) and individuals were classified as having asymptomatic *Plasmodium* parasitemia with no fever (AS), symptomatic *Plasmodium* parasitemia with an axillary temperature  $\geq 37.5^\circ\text{C}$  (SY) and non-infected (NI) (no *Plasmodium* parasitemia and a normal body temperature). Asymptomatic individuals were followed for 10 weeks before being treated with artemisinin-based combination treatment (ACT) and a final sample taken at week 16, 5 weeks after treatment. Those who continued to carry *Plasmodium* parasites with no measureable fever were defined as having chronic asymptomatic malaria. Antibody levels to *P. falciparum* schizont extract (SE), merozoite extract (ME), erythrocyte binding antigen-175 (EBA-175) and merozoite surface protein-1 (MSP-1) were quantified by ELISA. The growth inhibitory activities of circulating anti-parasite antibodies were quantified using the 3D7 laboratory strain of *P. falciparum* and a Sybr Green-I based parasite growth inhibition assay. Plasma levels of 38 cytokines were measured by Luminex technology.

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## **Results:**

Amongst infected individuals, parasitemia significantly decreased with increased age although this decrease in parasitemia with age was only observed until age 20. Individuals older than 20 years of age had low parasitemia and this remained constant between the ages of 20 and 80. Although there was no difference in the magnitude of the antibody response between AS, SY and NI groups to any of the antigens tested, median levels of antibody against *P. falciparum* crude extracts and recombinant proteins EBA-175 and MSP-1 were significantly higher in those older than 20 years of age compared with the younger age group as might be expected from lower parasite levels. Parasite densities and *P. falciparum* clones fluctuated widely over the 10-week follow-up period in individuals with persistent asymptomatic parasitemia but collectively there was no change in the antibody levels over time within this group. Similar to antibody levels, many levels of the cytokines measured were stable over time. However, IL-10 levels decreased after treatment indicating that this cytokine was associated with parasite carriage in asymptomatic individuals. The ratio of IL-10 to pro-inflammatory cytokines, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and lymphotoxin- $\alpha$  (LT- $\alpha$ ) ratios were higher in the symptomatic group compared to the asymptomatic individuals but only in the younger (<20 years old) age group.

**Conclusion:** Taken together, the above findings indicate that asymptomatic carriage of *Plasmodium falciparum* in children living in a hyperendemic area occurs independently of antibody responses, but is associated with induction of IL-10.

## Introduction

Malaria remains one of the most devastating human diseases in the world, causing an estimated 214 million cases and 627 000 deaths in 2020 (1). Since 2000, malaria incidence and mortality rates have decreased considerably (2) but this has been paralleled by high increases in proportions of asymptomatic infections, known to contribute significantly to persistent malaria transmission in most endemic countries (3–5). The host-parasite determinants and environmental risk factors of asymptomatic *Plasmodium* infections remain poorly defined. Asymptomatic infections can persist for weeks to years (6,7), with an oscillation of parasite densities over time (8). Epidemiological and immunological data implicates both host immune responses and parasite factors in the maintenance of chronic asymptomatic malaria (4,9). The host determinants of asymptomatic *Plasmodium* infections are thought to involve two main immunological processes (4,10): anti-parasite immunity that directly suppress parasite growth resulting to low infection densities (below the pyrogenic threshold) and anti-disease immunity which modulates clinical manifestations of the infection despite high infection loads. In either case, the contributions of anti-parasite or anti-disease immune processes to the maintenance of persistent asymptomatic *Plasmodium* infections remain unclear.

Untreated *P. falciparum* infections have been shown persist on average for 6 months, with fluctuations in parasite density over the course of an infection (8,11–14). Older children and adults have more cumulative exposure to parasite variants circulating within the community, developing adaptive responses to control parasite numbers and temper the inflammatory responses characteristic of malaria pathogenesis (15–17). Antibodies may control parasite replication or clearance via a number of mechanisms, including inhibition of merozoite egress and invasion, antibody-dependent cellular inhibition, complement-mediated lysis or opsonic phagocytosis and antibody-dependent respiratory burst activity by polymorphonuclear neutrophils (18–22). However, asymptomatic infections have been documented in younger children < 5 years with low level of immunity (23,24), suggesting that asymptomatic malaria is differentially controlled by innate and adaptive immune responses depending on age.

Anti-parasite immunity, which is acquired with age or exposure (9,25,26), is mediated mainly by anti-Plasmodial antibody responses, although could also involve regulated cytokine responses, that together suppress parasite growth, thus limiting parasitemia below the pyrogenic threshold, which eventually protects against clinical disease (4,10). Given that the symptoms of malaria are based in the induction of inflammation, anti-disease immunity likely operates via the suppression of inflammation. The outcome of the infection depends on the balance between anti- and pro-inflammatory cytokine responses leading to protection or pathogenesis (27,28). This could occur via a decrease in levels of pro-inflammatory immune mediators such as IFN- $\gamma$ , TNF- $\alpha$ , or an increase in anti-inflammatory mediators such as IL-10, TGF- $\beta$  (28–32) leading to tolerance of the infection (33–37). It has previously been hypothesized that, asymptomatic infections are associated with a shift in host immune responses towards an anti-inflammatory profile after multiple exposures to malaria (38).

It is currently unknown how anti-Plasmodial antibodies and cytokine responses are maintained over time to continuously protect against the development of symptoms during a *Plasmodium* infection. In asymptomatic individuals, it has been suggested that persistence parasitemia is essential for the maintenance of anti-malarial immunity, the disruption of which could result in increased host susceptibility to severe disease (39–41). By enrolling highly exposed individuals of all ages, this study aimed to determine whether or not asymptomatic infections is

associated with acquired antibody and cytokine responses in children as well as in adults. Furthermore, we monitored the stability of antibody and cytokine responses in chronically asymptomatic individuals over a 3-month period. At the end of this period of time we treated participants with ACT to determine which responses were dependent on the presence of circulating parasites. Our results suggest that antibodies are not the main immune mediator of chronic asymptomatic malaria in highly-exposed children and that IL-10 responses were dependent on the presence of *Plasmodium* parasites, but may be a marker of inflammation rather than the main mediator suppressing symptoms of malaria.

## Material and methods

### Ethics statement

The study protocol was approved by the Cameroon National Ethics Committee for Human Health Research (Ethical clearance N°: 2018/09/1104/CE/CNERSH/SP) and the Ministry of Public Health. Written informed consent was obtained from each participant or parent/guardian of minor participants (< 19 years old) prior to enrolment into the study. Assent was obtained from all children older than 12 years of age.

### Study area and population

The study population consisted of individuals of both genders aged at least two years of age and permanently living in one of the five selected villages of the Esse health district, Mefou-et-Afamba Division, Centre Region of Cameroon where malaria transmission is perennial, stable and hyper-endemic with *P. falciparum* as the predominant *Plasmodial* species. The study area has been described elsewhere (42,43). The inclusion criteria were: i) obtain the consent of each older participant or parent or legal guardian for the children, ii) living permanently in the study area, iii) not pregnant.

### Study design and participants

This was a longitudinal household-based study. Participants were considered asymptomatic for malaria if positive for *P. falciparum* using multiplex nested PCR in the absence of fever at least forty-eight hours prior to enrolment. Being febrile was assessed based on axillary temperature  $\geq 37.5$  °C or based on the history of fever as independently confirmed by another household member. All symptomatic individuals (fever + rapid diagnostic test (RDT) +) were treated with ACT-based drugs following recommended national guidelines. Participants with asymptomatic carriage of *Plasmodium* parasites were monitored weekly until they either developed a fever, or until the end of the follow up period at week 16 post-enrolment. Participant follow-up comprised of weekly interviews regarding the occurrence of fever during the past week, measurement of axillary temperatures on each visit, and laboratory testing for malaria at weeks 1, 4, 11 and 16 (PCR and microscopy). All symptomatic cases occurring during the follow-up period were treated with ACTs as recommended, and excluded from further follow-up. At week 11 post-enrolment all participants with persisting asymptomatic parasitemia were further treated as recommended and monitored for five additional weeks to assess the effect of ACT-based antimalarial treatment on selected host immune responses. Participants with persistent asymptomatic parasitemia 10 weeks following enrolment were considered as non-converters whereas those who developed malaria-associated symptoms before week 11 post-enrolment were considered as converters.

## Blood sample collection, malaria diagnosis and parasite genotyping

Approximately 3 ml of venous blood was collected in EDTA-coated tubes and used for laboratory testing for malaria and blood hemoglobin levels as well as to obtain plasma for immunological analysis. Plasma was separated from the red blood cell (RBC) pellet by centrifugation (3500 RPM, 5 min) and stored at -80 °C until use. Blood hemoglobin levels were assessed using a portable Mission Hb haemoglobinometer (ACON Laboratories, USA).

Parasite density (parasites/ $\mu$ l) was determined by microscopic examination of Giemsa-stained thick blood smears. Parasite density was determined based on the number of parasites per at least 200 WBC count on a thick film, assuming a total white blood cell count of 8000 cells/ $\mu$ L of whole blood. A blood slide was considered positive when a concordant result was obtained by at least two independent microscopists and when a discrepancy occurred, a third microscopist was used for confirmation. A slide was considered negative if no parasites were detected after a count of 500 white blood cells.

Genomic DNA was extracted from dried blood spots using the Chelex method (44), and used to screen for *Plasmodium* infections by multiplex nested PCR targeting the 18S *ssrRNA* genes as described by Snounou *et al.* (45). Genotyping of *msp2* gene was performed by nested PCR on *P. falciparum* PCR positive samples as previously described (43,46).

## Case definitions for the study

Participants were defined as asymptomatic if positive for malaria parasites by PCR in the absence of fever at least 48 hours prior to enrolment. Febrile malaria was determined based on RDT, light microscopy or PCR positivity for malaria parasites and axillary temperature  $\geq 37.5$  °C or a history of fever in the past 48 hours. Converters were defined as asymptomatic individuals who had developed fever associated with *Plasmodium* infection during the 10-week infection follow-up period, whereas persistent asymptomatic (non-converters) represented the asymptomatic individuals who remained asymptomatic until anti-malarial treatment at the end of the infection follow-up period.

## Anti-Plasmodial antibody levels and avidity assessment

Plasma IgG antibody levels and avidity were determined by indirect ELISA method using *P. falciparum* Merozoite extract (ME), schizont extract (SE) or the recombinant proteins EBA-175 and MSP-1c19 as coating antigens. ME and SE were isolated from laboratory maintained *P. falciparum* 3D7 parasites as described previously (47,48), and used for protein extraction by freeze-thaw fractionation (49,50). The recombinant protein erythrocyte binding antigen EBA-175 (F3 region) was obtained from BEI Resources (MRA-1162), whereas *P. falciparum* Merozoite Surface Protein-1<sub>19</sub> (MSP1p19) was produced using a baculovirus-insect cell expression system (51).

96-well microplates (F96 CERT-Maxisorp) were coated with each antigen (2 mg/ml of ME and SE, 0.20 mg/ml of EBA-175 and 0.5 mg/ml of MSP-1c19) in 0.1 M bicarbonate buffer (for ME, SE and EBA-175) or PBS (for MSP-1) and incubated overnight at 4°C. Plasma samples were diluted (1/250) in PBS-T/1%BSA and used to measure anti-*Plasmodial* IgG as previously described (42,52,53). Plasma from non-exposed European blood donors were used as naive controls whereas a pool of IgG fractions from adults living in high malaria endemic areas was used as positive controls. Results were expressed as optical-density ratios (OD sample/mean OD naive control). For avidity testing, 100  $\mu$ L of 8 M urea in wash buffer (treated wells) or 100  $\mu$ L of wash buffer (untreated wells)

were added for 15 minutes at room temperature to the respective wells following primary antibody binding as previously described (54). Avidity indices (AI) were calculated as proportion of bound antibodies following urea treatment (Avidity index = [mean OD of treated wells /mean OD of untreated wells] × 100). Samples with OD ratios > 2, corresponding to mean OD naive control + 3SD were considered as seropositive. In addition, only seropositive samples were used for avidity testing.

### **Growth inhibition assay (GIA)**

GIA was performed using plasma from endemic and non-endemic individuals as previously described by Duncan *et al.* (55). Briefly, plasma samples were heat inactivated at 56 ° C for 20 min and a 1:20 ratio of 50% RBC was added to each sample and incubated at room temperature for 1 h to remove the RBC-reactive antibody. After spinning for 2 min at 13,000 x g to pellet the red blood cells, the supernatant was transferred to a 96-well V-bottom plate. Synchronized late trophozoite or early schizont (30-40 h) stages of *P. falciparum* 3D7 at 0.5% parasitemia were incubated with plasma for 48 h at 37 ° C (5% CO<sub>2</sub>, 5% O<sub>2</sub> and 90% N<sub>2</sub>) in the flat-bottom plate. The GIA harvest was carried out by the green SYBR green method: 80 µl of the culture were transferred to the black plate and 40 µl of SYBR green solution were added and incubated for 30 min at 37°C in the dark. Fluorescence corresponding to the amount of DNA in each well was measured using a Fluoroscan. Parasite growth inhibition (GI) activities of plasma antibodies were presented as: GI indices (%) = 100 x [1 - ((OD Immune sample - OD RBC) / (OD parasitized RBC - OD RBC))].

### **Determination of plasma cytokine levels**

Plasma concentrations of 38 immune mediators including interleukin (IL)-1 $\alpha$ , IL-1 $\beta$ , IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p40, IL-p70, IL-13, IL-15, IL-17A, Interferon (IFN)- $\alpha$ 2, IFN- $\gamma$ , tumor necrosis factor (TNF)- $\alpha$ , lymphotoxin- $\alpha$  (LT- $\alpha$ ), IFN- $\gamma$  induced protein (IP-10), monocyte chemoattractant protein (MCP)-1, MCP-3, macrophage inflammatory protein (MIP)-1 $\alpha$ , MIP-1 $\beta$ , Eotaxin, Fractalkine, human growth-regulated oncogene (GRO), Macrophage-derived chemokine (MDC), granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), sCD40L, FMS-like tyrosine kinase 3 ligand (Flt-3L), epidermal growth factor (EGF), fibroblast growth factor 2 (FGF-2), transforming growth factor alpha (TGF- $\alpha$ ) and vascular endothelial growth factor (VEGF) were determined by Luminex-based method using the Human Cytokine/Chemokine Magnetic Bead Panel MILLIPLEX MAP Kit (Cat. No. HCYTMAG-60K-PX38, EMD Millipore Corporation) according to the manufacturer's instructions. Briefly, 25 µL of premixed magnetic capture beads were incubated with equal volumes of plasma or diluted standard in a 96-well microplate placed on a horizontal plate shaker for 2 hours. After washing using a magnetic plate, plates were incubated with 25 µL/well of biotinylated detection antibodies for 1 hour at room temperature followed by 25 µL of streptavidin-PE in each well for 30 minutes at room temperature. Median fluorescence intensity was read on a Luminex MAGPIX Analyser (XMAP Technology) equipped with xPONENT software version 4.2. The relative concentration of each cytokine (pg/ml) in each sample was determined based on the automatically generated standard curve for each analyte. Analyte amounts less than the limit of detection for each cytokine were attributed the value of detection limit.

## Statistical analysis

Statistical analyses were performed using RStudio version 4.1.1 (56) and Graphpad Prism version 8.4.3 (Graphpad software, San Diego, California USA). Differences in antibody and cytokine distribution between two or more groups were determined using Wilcoxon signed rank test and Kruskal-Wallis test, respectively. Spearman rank correlation tests or linear regression were used to determine the correlation between quantitative variables. Differences in categorical variables were determined by chi-square tests. P-values < 0.05 were considered statistically significant. Factor analysis of mixed data (FAMD) with FactoMineR and factoextra packages was used to assess the association between cytokines levels and age and circulating parasite loads. The complexHeatmap and ggpubr packages were used to draw the heatmaps and the line plots, respectively. Given that the aim of this study was to determine the host immunological determinants in the maintenance of the asymptomatic infections, among the 353 individuals included, only participants with complete information on the study outcome during the longitudinal follow-up period were included in the analysis (n= 211). A total of 123 participants (initially asymptomatic) were considered to have dropped out, which includes all participants who missed at least one of the follow-up points (the predominant reason being farming far away from the enrolment site). Among the 25 PCR negative samples, 17 were excluded due to their positivity by light microscopy (microscopy+/PCR-). Three samples (2 symptomatic and 1 asymptomatic) were excluded because no cytokines were detected in the plasma.

## Results

### Asymptomatic malaria prevalence in the study area

A total of 353 residents of the Esse health district of Cameroon were screened for malaria using multiplex nested PCR. Overall, 328 residents (92.9%) were positive for *Plasmodium* infection, of which (266) 81.1% were asymptomatic and 63 (18.9%) were symptomatic (43). Given that the aim of this study was to determine the host immunological determinants in the maintenance of the asymptomatic infections, only a subset of individuals with known status during the longitudinal follow-up period were included in the analysis. This totaled 142 individuals with asymptomatic infection, 61 symptomatic individuals and 8 non-infected individuals. The gender, age and hemoglobin, and for those with parasites visible by microscopy, the circulating parasitemia levels were comparable between study groups (**Table 1**).

### Individuals >20 years old had more anti-parasite IgG and better control of *Plasmodium falciparum*-infected red blood cells (iRBCs)

To determine whether antibody responses acquired with repeated exposures over time contributed to the control of the parasite densities in highly exposed individuals, anti-*Plasmodial* IgG levels were measured in the study participants and their efficacy quantified using an *in vitro* parasite growth inhibition assay. As shown in **Figure 1A**, parasitemia significantly decreased with age ( $r = -0.49$ ,  $P < 0.0001$ ). However, this association was only applicable in individuals parasitemia less than 20 years old ( $r = -0.39$ ,  $P < 0.0001$ ) (**Figure 1B**). In our study population the levels of circulating iRBCs in *P. falciparum* infected older individuals was not associated with age ( $r = -0.09$ ,  $P = 0.6623$ ). Furthermore, a significantly higher proportion of sub-microscopic infections was observed in individuals aged > 20 years compared to those aged  $\leq 20$  years ( $P < 0.0001$ ) (**Figure 1C**). Based on the parasitemia distribution, the study population was divided into two groups aged  $\leq 20$  years and > 20 years old for further analyses.

In this study population, median levels of IgG against *P. falciparum* crude extracts from the merozoite (ME) and schizont (SE) stages were significantly higher in the older age group compared to the younger age group ( $P < 0.05$ ) (**Figure 2A**). This was mirrored by IgG reactive to *P. falciparum* recombinant proteins EBA-175 and MSP-1. IgG levels against *P. falciparum* crude extracts were positively correlated with age, although this correlation was observed only in the younger age group ( $r = 0.22$ ,  $P = 0.0077$  and  $r = 0.29$ ,  $P = 0.0004$  for ME and SE, respectively) (**Figure 2B**) with a trend towards a similar correlation for anti-MSP-1 IgG ( $r = 0.15$ ,  $P = 0.0764$ ) but not EBA-175 IgG ( $r = 0.01$ ,  $P = 0.8793$ ) (**Figure 2B**). This data suggests that in this study population it may take about 20 years to develop saturation of the anti-*Plasmodium* immune response despite high transmission and exposure.

To determine how the magnitude of IgG levels to *P. falciparum* correlated with the efficacy of the humoral response, we determined whether IgG levels were correlated with the levels of circulating iRBCs in the participants. IgG levels were not different between individuals with sub-microscopic parasitemia compared to those with parasite levels visible by light-microscopy (**Figure 3A**). However levels of IgG to *P. falciparum* crude extracts were negatively correlated with parasite densities at the microscopy detection limit in the both age groups ( $r = -0.26$ ,  $P = 0.007$  and  $r = -0.28$ ,  $P = 0.0035$  for ME and SE, respectively in the  $\leq 20$  year age group;  $r = -0.44$ ,  $P = 0.0314$  and  $r = -0.43$ ,  $P = 0.0348$  for ME and SE, respectively in the  $>20$  year age group) (**Figure S1**). Multivariate analysis in the younger age group using IgG levels and age as predictors showed that parasite densities at the detection limit of microscopy were independently predicted by both age (coef  $> -1.60$ ,  $P < 0.0001$ ) and antibody levels against crude extracts and EBA-175 (coef  $= -0.59$ ,  $P = 0.0471$ ; coef  $= -0.65$ ,  $P = 0.0322$  and coef  $= -0.41$ ,  $P = 0.0114$  for ME, SE and EBA-175, respectively). This data suggest that the humoral response is efficacious in controlling parasite density.

To determine whether this was the case we determined the invasion blocking capacity of the humoral response. IgG antibody avidity indexes were comparable between individuals with sub-microscopic parasitemia and those with parasite levels at the detection limit of light-microscopy ( $p > 0.05$ ) and did not correlate significantly with parasitemia in the both age groups (**Figure S2**). The invasion blocking capacity of the IgG generated did not differ between individuals with sub-microscopic and microscopic parasitemia in either the younger ( $P = 0.9465$ ) or older ( $P = 0.0790$ ) age groups, although there was a trend towards more invasion blocking capacity in older individuals with microscopic parasitemia (**Figure 3B**). In the younger age group with parasites visible by light microscopy, there was a negative correlation between circulating parasitemia levels and invasion blocking capacity in the younger age group ( $r = -0.19$ ,  $P = 0.0482$ ) (**Figure 3B**). Collectively this data suggests that the humoral response is has some capability in blocking parasite invasion, but sub-microscopic parasitemia may be maintained by immune mechanisms in addition to antibodies, or the non-invasion blocking functions of antibody in sub-microscopic carriage of parasitemia may be more important.

### **Persistence of fluctuating asymptomatic parasitemia in highly exposed individuals without alteration in IgG levels**

Of the 142 participants who completed the follow-up study as designed, 78 (54.9%) remained asymptomatic during the 10-weeks follow-up period, whereas 63 (44.4%) developed malaria-associated fevers and 1 (0.7%) resolved the infection in the absence of any known antimalarial treatment. The proportion of converters or non-converters was comparable between the younger and the older age groups (**Figure 4A**) suggesting that the conversion from an asymptomatic to symptomatic infection is independent of age in highly exposed individuals. In persistent asymptomatic parasite carriers, the median parasitemia decreased between weeks 1 and 4, then



significantly increased at week 11 in the both age groups (**Figure 4B**). Parasite densities fluctuated widely over the follow-up period from ultra-low parasitemia (sub-microscopic) to high parasitemia suggesting that asymptomatic carriage of *P. falciparum* occurs independently of circulating parasite numbers, even within individual participants.

To determine whether there was a change in the *P. falciparum* clonotypes circulating in the population, we quantified the clonotypes present in the circulation of *P. falciparum* infected individuals. Consistent with the fluctuation of parasite densities over time during persistent asymptomatic parasitemia, although some clones are present from week 1 to week 11, some disappear while others appear over time, indicating the fluctuation of the *P. falciparum* clone population over time during asymptomatic infections may be due to changes in the clonotypic make up of infection in individual participants (**Figure 4C**). To determine whether antibody responses contributed to the maintenance of the asymptomatic status in persistently infected individuals, anti-*Plasmodial* IgG was measured over time in long-term asymptomatic carriers. However, no significant changes in IgG levels against all antigens tested were observed during persistent asymptomatic infections, despite significant fluctuations in Plasmodium parasitemia and population structure (**Figure 4D**), indicating that persistent asymptomatic parasitemia may not affect anti-Plasmodial antibody levels in highly exposed individuals. There was no difference in the magnitude or efficacy of circulating IgG levels between asymptomatic and symptomatic participants at the first time point of the study (**Figure S3A**). However, in younger individuals where the invasion blocking capacity of IgG from asymptomatic malaria was better than that of symptomatic individuals (**Figure S3B**) despite no difference in circulating iRBC density (**Figure S3B**). Collectively, these data demonstrated that asymptomatic parasitemia may persist in some individuals with changes in circulating parasite densities and population over time, with no significant effect on the magnitude of the IgG levels in highly exposed individuals.

### **Persistent asymptomatic parasitemia is not associated with a particular cytokine profile in highly exposed individuals**

Given that symptoms of malaria are associated with inflammatory responses and the hypothesis that anti-inflammatory cytokines may be important in down-regulating this pathogenic inflammatory response, we measured pro- and anti-inflammatory cytokine levels in our study participants. We used a factor analysis of mixed data (FAMD) on cytokine data measured by Luminex along with age and circulating parasite density. This analysis indicates that levels of IL-10, TNF- $\alpha$ , MCP-1, and IP-10 were associated with age and parasite density (**Figures 5A and 5B**). Multivariate analysis using age and parasitemia as predictors showed that age independently predicted the levels of TNF- $\alpha$  (coef= -0.31,  $P < 0.0001$ ) with a significant drop between the ages of 10-20 and 20-40 years of age (**Figure 5C**). Circulating parasite densities independently predicted the levels of IL-10, TNF- $\alpha$  and MCP-1 (coef= 0.21,  $P < 0.0001$ ; coef= 0.09,  $P < 0.0001$  and coef= 0.06,  $P = 0.01$  for IL-10, TNF- $\alpha$  and MCP-1, respectively) with a significant increase in all of these cytokines between those who had low levels of microscopic parasitemia (circulating densities between the limit of detection of light microscopy of 37.2 parasites/ $\mu$ l and 413.1 parasites/ $\mu$ l) and high levels of parasitemia (circulating parasite densities  $> 413.1$  parasites/ $\mu$ l, representing the median parasitemia in the study population) (**Figure 5D**). This suggests that levels of inflammation may decrease with age and this is likely a reflection of better control of circulating parasite levels (**Figure 1**) which appear to influence the levels IL-10, TNF- $\alpha$  and MCP-1.

Interestingly, in participants with persistent asymptomatic malaria 30 out of the 38 cytokines measured in our Luminex assay fluctuated significantly over the follow-up period between weeks 1 and 11 (**Figure 5E**). However, no significant changes were observed in levels of IL-10, TNF- $\alpha$  and MCP-1. This data suggests that these may be key mediators of asymptomatic carriage of *P. falciparum*.

### **IL-10 and TNF- $\alpha$ levels are a reflection of parasite carriage, and IL-10 levels are associated with fever in children**

To further investigate the association of IL-10, TNF- $\alpha$  and MCP-1 with the protection against development of clinical symptoms of *P. falciparum* infection, we compared cytokine levels between individuals with persistent asymptomatic *P. falciparum* infection and symptomatic *P. falciparum* infections in the both age groups at the initial time point of our study. Of all of the cytokines we measured, we did not observe a consistent inflammatory signature in those with symptomatic infections compared with asymptomatic infections (**Figure 6A**). However, among the 38 biomarkers quantified, levels of both pro-inflammatory markers (IL-6 and MCP-1) and anti-inflammatory cytokine IL-1RA were significantly higher in individuals with symptomatic malaria compared to those with asymptomatic *P. falciparum* infections in the younger (<20 years) but not older (>20 years) age group (**Figure 6B**).

Although non-significant, levels of IL-10, but not TNF- $\alpha$  and INF- $\gamma$ , were lower in the asymptomatic compared to symptomatic participants (**Figure 6B**). The median ratio of IL-10 to TNF- $\alpha$  was significantly higher in the symptomatic group compared to the asymptomatic group in both age groups (**Figure 6C**) in agreement with previously published data on the development of more severe symptoms of malaria (57,58) that the ratio of IL-10 to TNF- $\alpha$  may reflect the regulation of the inflammatory response to dampen symptoms of malaria. In support of this, multivariate logistic regression analysis of factors significantly different between asymptomatic and symptomatic younger individuals showed that the IL-10-TNF- $\alpha$  ratio (coef= 2.28, P= 0.01298) and IL-1RA (coef= 2.19, P= 0.0208) levels accounted for most of the variation (independently predicted) associated with symptomatic carriage of *P. falciparum* in this study (**Table S1**).

In younger participants levels of IL-10 and TNF- $\alpha$ , but not INF- $\gamma$ , were significantly higher in infected participants than in non-infected participants (**Figure 6B**) indicating that these cytokines are induced upon infection in agreement with **Figure 5D**. Anti-malarial treatment with ACT on week 11 post-enrolment resulted in a significant decline in the IL-10 levels in the younger age group 5 weeks later at week 16 (**Figure 7A**). Thus IL-10 is a reflection of parasite carriage in this age group.

Overall, in the younger individuals, IL-10/pro-inflammatory cytokine ratios were significantly ( $p= 0.0152$  and  $p= 0.0349$  for IL-10-TNF- $\alpha$  and IL-10-IFN- $\gamma$  ratios, respectively) higher in the converters compared to the non-converters among younger age group (**Figure 7B**). Although non-significant, IL-10 levels were higher in the converters compared to the non-converters in the both age group. However, among all the 38 biomarkers quantify, only median levels of IL-8 were significantly higher in non-converters group compared to the converters individuals in the younger age group ( $p= 0.0420$ ) (**Figure 7B**). These data indicate the implication of IL-10 in the clinical malaria and suggest an important role of IL-8 in the maintenance of asymptomatic carriage of *P. falciparum* over extended durations.

## Discussion

Significant gaps exist in the understanding of the contribution of anti-parasite and anti-disease immunity in the persistent asymptomatic parasite carriage in areas with high transmission of *P. falciparum*. Here, we have undertaken a longitudinal follow-up study of *P. falciparum*-infected individuals with persistent asymptomatic malaria to determine whether or not asymptomatic infections is associated with changes in antibody and cytokine responses. In this study, we have assessed the systemic immune profiles in persistent asymptomatic *plasmodial* infections to determine the immune correlates associated with asymptomatic carriage of *P. falciparum*.

Consistent with the acquisition of immune response with age (15,59) older asymptomatic individuals had better control of circulating iRBCs with a greater proportion of sub-microscopic infections than younger individuals. This was associated with an increase in the quantity of circulating anti-parasite IgG, albeit with a similar functional capacity with respect to invasion blocking, and is likely due to cumulative exposure to malaria parasites over time. A longitudinal study by Rodriguez-Barraquer et al. spanning 4 years and involving 773 children aged between 6 months and 10 years old in Ugandan villages, showed that older children had lower parasite loads than younger ones and that frequently infected children had lower parasitemia than the less frequently infected children (60). However, the decrease in parasite densities with age in our study was only observed in individuals under 20 years old. IgG levels against *P. falciparum* crude extracts were positively correlated with age in the younger (<20 years), but not in the older (>20 years) age group, indicating that the gradual acquisition of the anti-parasite immune response may saturate by the age of 20. Interestingly, an age-structured mathematical model of malaria transmission showed that anti-parasite immunity which results in more rapid clearance of parasitemia has an approximate half-life of 20 years (61) supporting this idea. Although IgG levels were comparable between individuals with asymptomatic and symptomatic parasitemia, plasma from individuals in the younger group with asymptomatic parasitemia significantly inhibited parasite invasion *in vitro* compared to plasma from those with symptomatic malaria, in younger age group. Given that the parasitemia levels between asymptomatic and symptomatic individuals in this group were similar, this data may reflect the fact that antibodies control iRBCs through several mechanisms apart from invasion blocking such as facilitating opsonic phagocytosis by phagocytes by neutrophils (62). If such other metrics are similar between the 2 groups then invasion blocking effects may be hidden by the cumulative action of circulating antibodies. In addition, invasion blocking differences may be mediated by anti-parasite IgM (63,64) which would be present in the growth inhibition assays but not measured in the ELISAs we carried out. The importance of invasion inhibition activity *in vitro* is not clear with conflicting findings across published studies (65–67). The inconsistent results reported in studies of growth-inhibitory activity and protection against *Plasmodium* infection may be due to differences in *P. falciparum* transmission dynamics or genetic backgrounds of the study populations (67).

The longevity of asymptomatic falciparum malaria has been studied in several settings with the prevalence in naturally occurring infections ranging from 2 months in Vietnam (8), 5–6 months in a longitudinal study in Ghana (13) and 6–9 months in Myanmar (14). Over the course of our 3-month study, we have shown that there is a high rate of persistent asymptomatic *parasite* carriage in Cameroon (43). Mathematical modelling of existing data indicates that asymptomatic *P. falciparum* infections could last for as long as 13-years (68). Collectively, our findings and other data indicate that chronic carriage of *Plasmodium* parasites occurs in a wide range of settings, although the frequency and duration is likely context-specific and likely due to differences in malaria endemicity (5). However, it is clear from our study that in a high transmission setting few individuals develop sterile immunity to *P. falciparum*, with a large proportion converting to symptomatic malaria with the development of fever and uncomplicated malaria. The proportion of converters was comparable between the younger and the older age groups, suggesting that the conversion from an

asymptomatic to symptomatic infection is independent of age in highly exposed individuals. The reasons for this finding are not clear but may be related to the circulation of highly inflammatory parasite clonotypes (69,70) that overcome the pyrogenic threshold of individuals within the population over time. Indeed, our analysis indicates that the circulating *P. falciparum* parasite population is heterogeneous. Consistent with the oscillation of parasite densities over time reported in a Vietnam cohort (8), parasitemia in persistent asymptomatic infections in our study vary widely from patent high-density infections to ultralow-density sub-patent infections. This fluctuation of parasite densities over time is consistent with the fluctuation of the clonotypes of *P. falciparum* we observed at the different time point in our study. Although some clones were consistently present from week 1 to week 11, some disappeared over this time with new clonotypes appearing. This changes in circulating parasite densities and clonotypes over time suggest there is a dynamic interaction between the circulating parasite population and host defence mechanisms during persistent asymptomatic infections (5). Despite this dynamic interaction, median IgG against all antigens tested were stable over time in the persistent asymptomatic parasite carriers. In contrast to our findings, antibody responses to several *Plasmodium* antigens have been shown to rise over time in infected individuals living in a seasonal low malaria transmission setting in Thailand, which coincided with the rise to the peak of malaria transmission in the region (71). The stability in antibody responses found in our study could also be explained by the stability in malaria transmission in the study area and suggest a limited boosting in antibody responses by persistent parasitemia in high transmission settings.

Unlike the IgG responses measured, significant changes were observed in several pro- and anti-inflammatory cytokine levels over our 11-week study with no obvious signature associated with the asymptomatic carriage of *P. falciparum* compared to symptomatic individuals. Acute malaria infection is thought to be associated with an increase in inflammatory cytokine levels in the peripheral blood, which mediates cellular responses and contributes to parasite clearance, but can also be responsible for the symptoms and pathogenesis of severe malaria. Thus, dampened inflammatory cytokine responses by increased levels of regulatory cytokine response may serve to protect individuals from symptomatic disease while at the same time interfering with their ability to prevent re-infection. Previous studies have shown that the clinical outcome of malaria infection is largely dictated by the balance between pro-inflammatory and anti-inflammatory markers (27,31,72–74). In our study we observed consistent levels of IL-10 and TNF- $\alpha$  in the plasma of individuals with persistent asymptomatic carriage of *P. falciparum* with a corresponding consistent ratio of IL-10/TNF- $\alpha$  across all time point of our 11-week study.

Although largely considered an anti-inflammatory cytokine, particularly during the acute phase of *Plasmodium* infection (75) the role of IL-10 is contextual (76). Our study shows that production of this cytokine is driven and maintained by continuous *P. falciparum* infection with a significant drop within 5 weeks of clearing parasitemia by ACT treatment. A similar finding was also shown in a recent study from the Gambia (77). Along the similar lines, other studies have shown that malaria convalescence phase was associated with a significant decrease in IL-10, IFN- $\gamma$ , TNF- $\alpha$  cytokine levels (30,78,79)(75). IL-10 is an anti-inflammatory cytokine that is pleiotropic with anti-inflammatory effects that include inhibition of monocytes and macrophages in the production of inflammatory cytokines such as IL-6, TNF, and IL-1 (80). However, IL-10 production may also be a consequence of increased inflammation and may be beneficial by reducing the inflammatory response in the face of poorer control of peripheral parasites. In addition to IL-10, higher levels of IL-6, IL-1RA and MCP-1 were also associated with symptomatic infections in the younger age group of our study. Higher levels of IL-1RA and MCP-1 have been associated with a gradual increase in disease severity from healthy controls to uncomplicated malaria to cerebral malaria, and very high levels have been found in children who die of cerebral malaria (81,82). Like IL-10, IL-1RA is a potent anti-

inflammatory cytokine that can also play a critical role in controlling inflammation by regulating the function of the pro-inflammatory cytokine IL-1 (83). Notably, IL-10 is a potent inducer of IL-1RA, which may depict one of the mechanisms by which IL-10 exerts its anti-inflammatory effects (84). Similar to findings in a study of visceral Leishmaniasis where increased IL-10 levels were the primary predictor of clinical conversion from asymptomatic to symptomatic visceral leishmaniasis in some endemic areas (85), the clinical conversion from asymptomatic to symptomatic malaria in our study was linked to increased baseline levels of IL-10/TNF- $\alpha$  cytokine ratios in children at time point 0 of our study. Multivariate logistic regression showed that the IL-10/TNF- $\alpha$  ratio was independently associated with developing symptomatic malaria. We also found a significantly increased level of IL-8 at baseline in those who did not convert from asymptomatic malaria compared to those who did develop symptoms, but only in the group <20 years old. IL-8 is a chemoattractant cytokine known to be involved in neutrophil recruitment and activation, and previously associated with severe malaria pathogenesis (73,78). A recent study reported higher levels of IL-8 production by PBMCs from asymptomatic individuals compared to symptomatic carriers (86). Furthermore, the Malian Fulani ethnic group who are known to be less susceptible to *Plasmodium falciparum* malaria as reflected by lower parasitemia and fewer clinical symptoms exhibited a higher level of IL-8 than sympatric ethnic groups (87). Together, these findings suggest a potential dual role of IL-8 in the protection against clinical malaria and/or the development of the severe disease that might also depend on the timing of its release. Together, these findings suggest an important role of these cytokines in the maintenance of asymptomatic carriage of *P. falciparum* over extended durations. Most of the association between biomarkers and clinical malaria in this study were only found in the younger age group, but not in adults, indicating that the mechanisms of the protection against clinical malaria may be different according to age and the levels of exposure.

Taken together, the above findings indicate that asymptomatic carriage of *Plasmodium falciparum* in children living in a hyperendemic area occurs independently of IgG but is associated with IL-10. This data needs to be considered in light of the impending roll out of the RTS, S vaccine given the potential for interference of these responses with vaccine-mediated immune responses.

## Reference

1. WHO. World Malaria Report 2021. Geneva; 2021. Report No.: ISBN 978-92-4-001579-1.
2. Cibulskis RE, Alonso P, Aponte J, Aregawi M, Barrette A, Bergeron L, et al. Malaria: Global progress 2000 - 2015 and future challenges. *Infect Dis Poverty*. 2016 Jun;5(1):61.
3. Bousema T, Okell L, Felger I, Drakeley C. Asymptomatic malaria infections: detectability, transmissibility and public health relevance. *Nat Rev Microbiol*. 2014;12(12):833.
4. Galatas B, Bassat Q, Mayor A. Malaria Parasites in the Asymptomatic: Looking for the Hay in the Haystack. *Trends Parasitol*. 2016 Apr;32(4):296–308.
5. Drakeley C, Gonçalves B, Okell L, Slater H. Understanding the Importance of Asymptomatic and Low-Density Infections for Malaria Elimination. In: Manguin S, Dev V, editors. *Towards Malaria Elimination - A Leap Forward* [Internet]. InTech; 2018 [cited 2018 Sep 4]. Available from: <http://www.intechopen.com/books/towards-malaria-elimination-a-leap-forward/understanding-the-importance-of-asymptomatic-and-low-density-infections-for-malaria-elimination>
6. Ashley EA, White NJ. The duration of *Plasmodium falciparum* infections. *Malar J*. 2014;13(1):500.

7. Tripura R, Peto TJ, Chalk J, Lee SJ, Sirithiranont P, Nguon C, et al. Persistent *Plasmodium falciparum* and *Plasmodium vivax* infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. *Malar J*. 2016 Mar 24;15(1):181.
8. Nguyen T-N, von Seidlein L, Nguyen T-V, Truong P-N, Hung SD, Pham H-T, et al. The persistence and oscillations of submicroscopic *Plasmodium falciparum* and *Plasmodium vivax* infections over time in Vietnam: an open cohort study. *Lancet Infect Dis*. 2018 May;18(5):565–72.
9. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. *Clin Microbiol Rev*. 2009 Jan;22(1):13–36, Table of Contents.
10. Ademolue TW, Awandare GA. Evaluating antidisease immunity to malaria and implications for vaccine design. *Immunology*. 2018 Apr;153(4):423–34.
11. Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, et al. The temporal dynamics and infectiousness of subpatent *Plasmodium falciparum* infections in relation to parasite density. *Nat Commun [Internet]*. 2019 Mar 29 [cited 2020 Jun 4];10. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440965/>
12. Bretscher MT, Maire N, Chitnis N, Felger I, Owusu-Agyei S, Smith T. The distribution of *Plasmodium falciparum* infection durations. *Epidemics*. 2011 Jun 1;3(2):109–18.
13. Felger I, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, et al. The Dynamics of Natural *Plasmodium falciparum* Infections. Gosling RD, editor. *PLoS ONE*. 2012 Sep 18;7(9):e45542.
14. Landier J, Kajeewiwa L, Thwin MM, Parker DM, Chaumeau V, Wiladphaingern J, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant *falciparum* malaria: A pilot trial in four villages of Eastern Myanmar. *Wellcome Open Res*. 2017;2:81.
15. Doolan DL, Dobano C, Baird JK. Acquired immunity to malaria. *Clin Microbiol Rev*. 2009 Jan;22(1):13–36, Table of Contents.
16. Ademolue TW, Awandare GA. Evaluating antidisease immunity to malaria and implications for vaccine design. *Immunology*. 2018 Apr;153(4):423–34.
17. Kijogi C, Kimura D, Bao LQ, Nakamura R, Chadeka EA, Cheruiyot NB, et al. Modulation of immune responses by *Plasmodium falciparum* infection in asymptomatic children living in the endemic region of Mbita, western Kenya. *Parasitol Int*. 2018 Jun;67(3):284–93.
18. Duncan CJA, Hill AVS, Ellis RD. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? *Hum Vaccines Immunother*. 2012 Jun;8(6):706–14.
19. Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspelting-Jones H, et al. Human Antibodies Fix Complement to Inhibit *Plasmodium falciparum* Invasion of Erythrocytes and Are Associated with Protection against Malaria. *Immunity*. 2015 Mar;42(3):580–90.
20. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against *Plasmodium falciparum* blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. *J Exp Med*. 1990 Dec 1;172(6):1633–41.

21. Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, et al. Opsonic phagocytosis of *Plasmodium falciparum* merozoites: mechanism in human immunity and a correlate of protection against malaria. *BMC Med*. 2014;12(1):108.
22. Joos C, Marrama L, Polson HEJ, Corre S, Diatta A-M, Diouf B, et al. Clinical Protection from *Falciparum* Malaria Correlates with Neutrophil Respiratory Bursts Induced by Merozoites Opsonized with Human Serum Antibodies. Beeson JG, editor. *PLoS ONE*. 2010 Mar 25;5(3):e9871.
23. Ouédraogo M, Samadoulougou S, Rouamba T, Hien H, Sawadogo JEM, Tinto H, et al. Spatial distribution and determinants of asymptomatic malaria risk among children under 5 years in 24 districts in Burkina Faso. *Malar J*. 2018 Dec 7;17:460.
24. Okyere B, Owusu-Ofori A, Ansong D, Buxton R, Benson S, Osei-Akoto A, et al. Point prevalence of asymptomatic *Plasmodium* infection and the comparison of microscopy, rapid diagnostic test and nested PCR for the diagnosis of asymptomatic malaria among children under 5 years in Ghana. *PloS One*. 2020;15(7):e0232874.
25. White M, Watson J. Age, exposure and immunity. *eLife* [Internet]. [cited 2021 Mar 31];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103766/>
26. Griffin JT, Hollingsworth TD, Reyburn H, Drakeley CJ, Riley EM, Ghani AC. Gradual acquisition of immunity to severe malaria with increasing exposure. *Proc R Soc B Biol Sci*. 2015 Jan 7;282(1801):20142657–20142657.
27. Rovira-Vallbona E, Moncunill G, Bassat Q, Aguilar R, Machevo S, Puyol L, et al. Low antibodies against *Plasmodium falciparum* and imbalanced pro-inflammatory cytokines are associated with severe malaria in Mozambican children: a case–control study. *Malar J*. 2012 May 30;11:181.
28. Andrade BB, Santos CJN, Camargo LM, Souza-Neto SM, Reis-Filho A, Clarêncio J, et al. Hepatitis B Infection Is Associated with Asymptomatic Malaria in the Brazilian Amazon. *PLOS ONE*. 2011 May 18;6(5):e19841.
29. Guiyedi V, Bécavin C, Herbert F, Gray J, Cazenave P-A, Kombila M, et al. Asymptomatic *Plasmodium falciparum* infection in children is associated with increased auto-antibody production, high IL-10 plasma levels and antibodies to merozoite surface protein 3. *Malar J* [Internet]. 2015 Dec [cited 2018 Feb 5];14(1). Available from: <http://www.malariajournal.com/content/14/1/162>
30. Gonçalves RM, Scopel KK, Bastos MS, Ferreira MU. Cytokine balance in human malaria: does *Plasmodium vivax* elicit more inflammatory responses than *Plasmodium falciparum*? *PLoS One*. 2012;7(9):e44394.
31. Wilson NO, Bythwood T, Solomon W, Jolly P, Yatich N, Jiang Y, et al. Elevated levels of IL-10 and G-CSF associated with asymptomatic malaria in pregnant women. *Infect Dis Obstet Gynecol*. 2010;2010.
32. Luty AJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, Greve B, et al. Interferon-gamma responses are associated with resistance to reinfection with *Plasmodium falciparum* in young African children. *J Infect Dis*. 1999 Apr;179(4):980–8.

33. Jagannathan P, Kim CC, Greenhouse B, Nankya F, Bowen K, Eccles-James I, et al. Loss and dysfunction of  $V\delta^+$   $\gamma\delta$  T cells are associated with clinical tolerance to malaria. *Sci Transl Med*. 2014 Aug 27;6(251):251ra117.
34. Bediako Y, Ngoi JM, Nyangweso G, Wambua J, Opiyo M, Nduati EW, et al. The effect of declining exposure on T cell-mediated immunity to *Plasmodium falciparum* – an epidemiological “natural experiment.” *BMC Med*. 2016 Sep 22;14(1):143.
35. Portugal S, Moebius J, Skinner J, Doumbo S, Doumtabe D, Kone Y, et al. Exposure-dependent control of malaria-induced inflammation in children. *PLoS Pathog*. 2014 Apr;10(4):e1004079.
36. Ademolue TW, Aniweh Y, Kusi KA, Awandare GA. Patterns of inflammatory responses and parasite tolerance vary with malaria transmission intensity. *Malar J*. 2017 Dec;16(1):145.
37. Hirunpetcharat C, Finkelman F, Clark IA, Good MF. Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease. *Parasite Immunol*. 1999;21(6):319–29.
38. Kimenyi KM, Wamae K, Ochola-Oyier LI. Understanding *P. falciparum* Asymptomatic Infections: A Proposition for a Transcriptomic Approach. *Front Immunol* [Internet]. 2019 [cited 2019 Dec 12];10. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803459/>
39. Smith T, Felger I, Tanner M, Beck HP. Premunition in *Plasmodium falciparum* infection: insights from the epidemiology of multiple infections. *Trans R Soc Trop Med Hyg*. 1999 Feb;93 Suppl 1:59–64.
40. Baird JK. Host Age as a determinant of naturally acquired immunity to *Plasmodium falciparum*. *Parasitol Today*. 1995 Mar 1;11(3):105–11.
41. Sergent E. Définition of Immunity and Premunition. *J Ann Inst Pasteur*. 1950;79(5):786–97.
42. Essangui E, Moukoko CEE, Nguedia N, Tchokwansi M, Banlanjo U, Maloba F, et al. Demographical, hematological and serological risk factors for *Plasmodium falciparum* gametocyte carriage in a high stable transmission zone in Cameroon. *PLOS ONE*. 2019 Apr 25;14(4):e0216133.
43. Fogang B, Biabi MF, Megnekou R, Maloba FM, Essangui E, Donkeu C, et al. High Prevalence of Asymptomatic Malarial Anemia and Association with Early Conversion from Asymptomatic to Symptomatic Infection in a *Plasmodium falciparum* Hyperendemic Setting in Cameroon. *Am J Trop Med Hyg*. 2021 Nov 1;tpmd210316.
44. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in *Plasmodium falciparum* dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. *Am J Trop Med Hyg*. 1995 Jun;52(6):565–8.
45. Snounou G, Pinheiro L, Gonçalves A, Fonseca L, Dias F, Brown KN, et al. The importance of sensitive detection of malaria parasites in the human and insect hosts in epidemiological studies, as shown by the analysis of field samples from Guinea Bissau. *Trans R Soc Trop Med Hyg*. 1993 Nov 1;87(6):649–53.
46. Ranford-Cartwright LC, Taylor J, Umasunthar T, Taylor LH, Babiker HA, Lell B, et al. Molecular analysis of recrudescence parasites in a *Plasmodium falciparum* drug efficacy trial in Gabon. *Trans R Soc Trop Med Hyg*. 1997 Nov 1;91(6):719–24.



47. Quintana M del P, Ch'ng J-H, Zandian A, Imam M, Hultenby K, Theisen M, et al. SURGE complex of *Plasmodium falciparum* in the rhoptry-neck (SURFIN4.2-RON4-GLURP) contributes to merozoite invasion. *PLOS ONE*. 2018 Aug 9;13(8):e0201669.
48. Boyle MJ, Wilson DW, Richards JS, Riglar DT, Tetteh KKA, Conway DJ, et al. Isolation of viable *Plasmodium falciparum* merozoites to define erythrocyte invasion events and advance vaccine and drug development. *Proc Natl Acad Sci*. 2010 Aug 10;107(32):14378–83.
49. Heiber A, Spielmann T. Preparation of parasite protein extracts and western blot analysis. *Bio-Protoc*. 2014;4:e1136.
50. Rungsihirunrat K, Chaijaroenkul W, Siripoon N, Seugorn A, Thaithong S, Na-Bangchang K. Comparison of protein patterns between *Plasmodium falciparum* mutant clone T9/94-M1-1(b3) induced by pyrimethamine and the original parent clone T9/94. *Asian Pac J Trop Biomed*. 2012 Jan;2(1):66–9.
51. Bonnet S, Pêtres S, Holm I, Fontaine T, Rosario S, Roth C, et al. Soluble and glyco-lipid modified baculovirus *Plasmodium falciparum* C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate. *Vaccine*. 2006 Aug;24(33–34):5997–6008.
52. Perraut R, Varela M-L, Joos C, Diouf B, Sokhna C, Mbengue B, et al. Association of antibodies to *Plasmodium falciparum* merozoite surface protein-4 with protection against clinical malaria. *Vaccine*. 2017 04;35(48 Pt B):6720–6.
53. Perraut R, Varela M-L, Loucoubar C, Niass O, Sidibé A, Tall A, et al. Serological signatures of declining exposure following intensification of integrated malaria control in two rural Senegalese communities. *PLoS ONE* [Internet]. 2017 Jun 13 [cited 2019 Sep 8];12(6). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469466/>
54. Berry AA, Gottlieb ER, Kouriba B, Diarra I, Thera MA, Dutta S, et al. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with *Plasmodium falciparum* apical membrane antigen 1 vaccine candidate FMP2.1/AS02 A. *Malar J*. 2019 Dec;18(1):13.
55. Duncan EH, Bergmann-Leitner ES. Miniaturized Growth Inhibition Assay to Assess the Anti-blood Stage Activity of Antibodies. In: Vaughan A, editor. *Malaria Vaccines* [Internet]. New York, NY: Springer New York; 2015 [cited 2019 Apr 30]. p. 153–65. Available from: [http://link.springer.com/10.1007/978-1-4939-2815-6\\_13](http://link.springer.com/10.1007/978-1-4939-2815-6_13)
56. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. R Foundation for Statistical Computing; 2021. Available from: <https://www.R-project.org/>
57. Othoro C, Aa L, B N, D K, As O, V U. A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. *J Infect Dis*. 1999 Jan;179(1):279–82.
58. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. Plasma interleukin-10:Tumor necrosis factor (TNF)-alpha ratio is associated with TNF promoter variants and predicts malarial complications. *J Infect Dis*. 2000 Nov;182(5):1570–3.
59. White M, Watson J. Age, exposure and immunity. *eLife* [Internet]. 2021 Mar 31 [cited 2021 Mar 31];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103766/>

60. Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kanya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. *eLife*. 2018;7:e35832.
61. Filipe JAN, Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC. Determination of the Processes Driving the Acquisition of Immunity to Malaria Using a Mathematical Transmission Model. *PLOS Comput Biol*. 2007 Dec 28;3(12):e255.
62. Garcia-Senosian A, Kana IH, Singh S, Das MK, Dziegiel MH, Hertegonne S, et al. Neutrophils dominate in opsonic phagocytosis of *P. falciparum* blood-stage merozoites and protect against febrile malaria. *Commun Biol*. 2021 Aug 19;4(1):984.
63. Hopp CS, Sekar P, Diouf A, Miura K, Boswell K, Skinner J, et al. Plasmodium falciparum-specific IgM B cells dominate in children, expand with malaria, and produce functional IgM. *J Exp Med*. 2021 Apr 5;218(4):e20200901.
64. Thouvenel CD, Fontana MF, Netland J, Krishnamurty AT, Takehara KK, Chen Y, et al. Multimeric antibodies from antigen-specific human IgM<sup>+</sup> memory B cells restrict Plasmodium parasites. *J Exp Med*. 2021 Apr 5;218(4):e20200942.
65. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J, et al. Antibody-Mediated Growth Inhibition of Plasmodium falciparum: Relationship to Age and Protection from Parasitemia in Kenyan Children and Adults. Sutherland CJ, editor. *PLoS ONE*. 2008 Oct;3(10):e3557.
66. McCallum FJ, Persson KEM, Mugenyi CK, Fowkes FJI, Simpson JA, Richards JS, et al. Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum. *PLoS ONE*. 2008 Oct 29;3(10):e3571.
67. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, et al. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. *Infect Immun*. 2010 Feb;78(2):737–45.
68. Ashley EA, White NJ. The duration of Plasmodium falciparum infections. *Malar J*. 2014;13(1):500.
69. Corrigan RA, Rowe JA. Strain variation in early innate cytokine induction by Plasmodium falciparum. *Parasite Immunol*. 2010 Jul;32(7):512–27.
70. Allan RJ, Rowe A, Kwiatkowski D. Plasmodium falciparum varies in its ability to induce tumor necrosis factor. *Infect Immun*. 1993 Nov;61(11):4772–6.
71. Baum E, Sattabongkot J, Sirichaisinthop J, Kiattibutr K, Jain A, Taghavian O, et al. Common asymptomatic and submicroscopic malaria infections in Western Thailand revealed in longitudinal molecular and serological studies: a challenge to malaria elimination. *Malar J*. 2016 Jun 22;15:333.
72. Prakash D, Fesel C, Jain R, Cazenave P-A, Mishra GC, Pied S. Clusters of cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic areas of Central India. *J Infect Dis*. 2006 Jul 15;194(2):198–207.
73. Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, Diarra I, et al. Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis

- factor alpha, and IL-12(p70) in Malian children with severe *Plasmodium falciparum* malaria and matched uncomplicated malaria or healthy controls. *Infect Immun*. 2004 Oct;72(10):5630–7.
74. Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, Chau TT, et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. *J Infect Dis*. 1999 Oct;180(4):1288–97.
  75. Rodrigues-da-Silva RN, Lima-Junior J da C, Fonseca B de PF e, Antas PRZ, Baldez A, Storer FL, et al. Alterations in cytokines and haematological parameters during the acute and convalescent phases of *Plasmodium falciparum* and *Plasmodium vivax* infections. *Mem Inst Oswaldo Cruz*. 2014 Apr;109(2):154–62.
  76. Kumar R, Ng S, Engwerda C. The Role of IL-10 in Malaria: A Double Edged Sword. *Front Immunol* [Internet]. 2019 [cited 2019 Aug 30];10. Available from: <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00229/full>
  77. Mooney JP, DonVito SM, Jahateh M, Bittaye H, Keith M, Galloway LJ, et al. “Bouncing Back” From Subclinical Malaria: Inflammation and Erythrocytosis After Resolution of *P. falciparum* Infection in Gambian Children. *Front Immunol*. 2022;13:780525.
  78. Mandala WL, Msefula CL, Gondwe EN, Drayson MT, Molyneux ME, MacLennan CA. Cytokine Profiles in Malawian Children Presenting with Uncomplicated Malaria, Severe Malarial Anemia, and Cerebral Malaria. *Clin Vaccine Immunol CVI* [Internet]. 2017 Apr 5 [cited 2019 Aug 30];24(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382826/>
  79. Rodrigues-da-Silva RN, Lima-Junior J da C, Fonseca B de PF e, Antas PRZ, Baldez A, Storer FL, et al. Alterations in cytokines and haematological parameters during the acute and convalescent phases of *Plasmodium falciparum* and *Plasmodium vivax* infections. *Mem Inst Oswaldo Cruz*. 2014 Apr;109(2):154–62.
  80. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. *J Exp Med*. 1991 Nov 1;174(5):1209–20.
  81. Jakobsen PH, McKay V, Morris-Jones SD, McGuire W, van Hensbroek MB, Meisner S, et al. Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. *Infect Immun*. 1994 Oct;62(10):4374–9.
  82. John CC, Park GS, Sam-Agudu N, Opoka RO, Boivin MJ. Elevated serum levels of IL-1ra in children with *P. falciparum* malaria are associated with increased severity of disease. *Cytokine*. 2008 Mar;41(3):204–8.
  83. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. *Annu Rev Immunol*. 1998;16:27–55.
  84. Tamassia N, Castellucci M, Rossato M, Gasperini S, Bosisio D, Giacomelli M, et al. Uncovering an IL-10-dependent NF-kappaB recruitment to the IL-1ra promoter that is impaired in STAT3 functionally defective patients. *FASEB J Off Publ Fed Am Soc Exp Biol*. 2010 May;24(5):1365–75.

85. Topno RK, Kumar R, Pandey K, Dikhit MR, Madhukar M, Kumar M, et al. Early diagnostic marker for the conversion of asymptomatic to symptomatic visceral leishmaniasis. *J Med Allied Sci.* 2019;9(2):96–9.
86. Lehmann JS, Campo JJ, Cicéron M, Raccurt CP, Boncy J, Beau De Rochars VEM, et al. T cell subtypes and reciprocal inflammatory mediator expression differentiate *P. falciparum* memory recall responses in asymptomatic and symptomatic malaria patients in southeastern Haiti. Braga ÉM, editor. *PLOS ONE.* 2017 Apr 3;12(4):e0174718.
87. Boström S, Giusti P, Arama C, Persson J-O, Dara V, Traore B, et al. Changes in the levels of cytokines, chemokines and malaria-specific antibodies in response to *Plasmodium falciparum* infection in children living in sympatry in Mali. *Malar J.* 2012 Apr 5;11(1):109.

### **Acknowledgements**

We thank the field staff and, most importantly, residents of the Esse Health district in Cameroon who participated in this study.

### **Financial Support:**

This work was financial supported through a capacity building grant from the Institute Pasteur International Division to LA.

### **Author contributions:**

BF devised the experiments, performed the experiments, analyzed data, and drafted the paper; FM performed fieldwork, sample processing and experiments; MFA, EE, CD, GC, MK, RK and SK performed fieldwork and sample processing; MS and RP provided cytokine kits and recombinant plasmodial antigens, respectively and reviewed paper. RM supervised the experiments and reviewed paper; LA and TL devised the experiments, supervised the experiments, analyzed data, and wrote the paper.

### **Competing interests**

Authors declare no competing interests.

## Tables and figures

**Table 1. Characteristics of the study population**


Variables	Non-infected (n= 8)	Asymptomatic (n= 142)	Symptomatic (n= 61)	P value
Sex ratio (M:F)	0.6 (3:5)	0.67 (57:85)	0.90 (29:32)	0.5967
Median age, years (range)	18 (4-68)	13 (2–86)	11 (2–80)	0.0695
Median Hb, g/dl (range)	11.9 (10.7-14)	12.2 (4.9-16)	11.8 (6.8-16.6)	0.2047
% of submicroscopic % (n)	-	35.2 (50)	24.6 (15)	0.6552
Median arasaemia, parasites/ $\mu$ l (range)	-	313.7 (37.4-68153)	511.7 (37.2-240457)	0.1370

P-value was determined using Wilcoxon signed-rank test and Kruskal-Wallis test when comparing two or three groups, respectively. The median parasitemia presented in this table is only for the infected individuals with parasite densities at the detection limit of light microscopy. Hb: hemoglobin. M: male. F: female


**Table S1. Multivariate logistic regression analysis of selected cytokines**

Cytokines	Coefficients	P value
IL-10	-1.19	0.1828
<b>IL-1RA</b>	<b>2.18</b>	<b>0.0208</b>
MCP-1	1.80	0.1026
IP-10	0.87	0.2558
IL-6	-0.35	0.5888
<b>IL-10/TNF-<math>\alpha</math></b>	<b>2.28</b>	<b>0.0130</b>


The data in this table represents the results of multivariate logistic regression analysis of selected cytokines with p-value <0.1 when comparing individuals with asymptomatic *Plasmodium* infection to those with symptomatic infection.



**Fig 1. Older individuals (>20 years) have a better control of parasite densities.** A) Scatterplot showing a correlation between parasite densities and age in all the infected individuals with parasitemia at the detection limit of light microscopy (n= 138). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-value (p), are shown. The red straight line was used to divide the study population into two groups aged ≤ 20 years and > 20 years old for further analyses. B) Scatterplot of correlation between parasitemia and age in different age groups (≤ 20 years and > 20 years). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-value (p), are shown for each age group. C) The pie chart shows the proportion of sub-microscopic infections (PCR+/microscopy-) versus microscopic (microscopy+) infections in each age group. PCR: Polymerase Chain Reaction.




**Fig 2. Individuals >20 years old had more anti-parasite IgG.** A) Data presented in the scatterplot represent IgG antibody levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1) within age groups. Median levels between age groups were compared by Wilcoxon signed-rank test and the p-values are shown on the plot. B) The scatterplots on B show the correlation between IgG levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1) and age in different age groups ( $\leq 20$  years and  $> 20$  years). Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-values (p), are shown for each age group. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1: Merozoite surface protein-1. OD: optical density.




**Fig 3. IgG anti-*Plasmodial* antibody levels and parasitemia levels (A), and anti-parasite growth inhibition activities (B).** A) Data presented in the scatterplots represent IgG antibody levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1) in sub-microscopic and microscopic groups, according to age groups. Median levels between parasitemia groups were compared by Wilcoxon signed-rank test and the p-values are shown on the plot. B) The scatterplots on the left show *P. falciparum* growth inhibition activities of circulating plasma antibodies in sub-microscopic and microscopic groups. Median antibody GI index between parasitemia groups were compared by Wilcoxon signed-rank test and the p-values are shown on the plot. The scatterplots on the right show the correlation between *P. falciparum* growth inhibition activities of circulating antibodies and parasitemia in different age groups. Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-values (p), are shown for each age group. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1: Merozoite surface protein-1. GI: Growth inhibition. OD: optical density.







**Fig 4. Asymptomatic malaria can persist in some individuals despite changes in the circulating parasite densities and population over time, but not affect the antibody levels.** A) The pie charts show the proportion of individuals with initial asymptomatic infection (cross-sectional) who resolved the infection (clearers), developed malaria associated fever (converters) or remained asymptomatic (non-converters) over the 10-week follow-up period, according to age groups. B) Data presented in the line plots represent parasitemia in each chronic asymptotically infected individual at three different time points (week 1, 4 and 11) in the age groups. Data shown as median were analyzed by nonparametric Kruskal–Wallis test for multiple comparisons and Wilcoxon signed-rank test for comparison between two groups. C) Pie charts show the proportion of *msp2* alleles (representing the clones) determined by nested PCR in individuals with persistent asymptomatic infection per week. Blue slices represent the alleles only present at week 1. Red slices represent the alleles which appear at week 4. Purple slices represent the allele only present at week 11. Grey slices represent the alleles that were present at all three sampling time points (bands of 375, 400, 475, 500, 520, 534, 540, 600, 620, 633, 680, 700, 800 bp). D) Data presented in the line plots represent the profile of IgG anti-*Plasmodial* antibody levels in each chronic asymptotically-infected individuals at three different time points (week 1, 4 and 11) in the two age groups. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1: Merozoite surface protein-1. OD: optical density.




**Fig 5. Cytokine responses are blunted with increased age and dependent on parasite densities.** A) Principal component of cytokines, age and parasitemia from FAMD analysis. B shows the contribution of each variable on the principal component 2 (dimension 2). C and D box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log10 pg/ml) measured by Luminex according to age and parasite level groups, respectively. Median levels of cytokines between two or more groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively. E) Hierarchical clustering of the standardized least-square means of 38 differentially expressed cytokines/chemokines/growth factors across the three sampling time points during asymptomatic infection follow-up. FAMD: Factor analysis of mixed data.




**Fig 6. IL-10 in associated with clinical malaria in the younger age group ( $\leq 20$  years).** A) Hierarchical clustering (heatmap) of the standardized least-square means of 38 differentially expressed cytokines/chemokines/growth factors across the three infection status. B and C box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log<sub>10</sub> pg/ml) measured by Luminex according to infection status. Median levels of cytokines between two or three groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively. NI: Non-infected. AS: Asymptomatic. SY: Symptomatic. \* $p < 0.05$ ; \*\* $p < 0.001$ ; \*\*\* $p < 0.0001$ .




**Fig 7. IL-10 and TNF- $\alpha$  levels are a reflection of parasite carriage, and IL-10 levels are associated with the development of fever in the younger age,  $\leq 20$  years.** A) Box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log<sub>10</sub> pg/ml) during persistent asymptomatic infections (week 1, 2 and 11) and after anti-malarial treatment (week 16). B) Box plots representing interquartile ranges (25th, median and 75th percentile, whisker percentile (1st and 99th)) of cytokine levels (Log<sub>10</sub> pg/ml) in converters and non-converters. Median cytokines levels between two or more groups were compared by Wilcoxon rank-sum test and Kruskal-Wallis test, respectively. \* $p < 0.05$ ; \*\*\* $p < 0.0001$ .



**Fig S1. Correlation between IgG anti-*Plasmodial* antibody levels and parasite loads.** Scatterplots show the correlation between IgG anti-*P. falciparum* antibody levels and parasitemia in different age groups. Spearman rank correlation is presented as the best fit line and the coefficient (r), as well as the p-values (p), are shown for each age group. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1: Merozoite surface protein-1. OD: optical density.



**Fig S2. No association between IgG anti-*Plasmodial* antibody avidity and age or parasite densities.** A) Data presented in the scatterplots represent IgG antibody avidity index against different *P. falciparum* antigens (EBA-175 and MSP-1) in sub-microscopic and microscopic groups, according to age groups. Median levels between parasitemia groups were compared by Wilcoxon signed-rank test. In B and C scatterplots show the correlation between IgG anti-*Plasmodial* antibody avidity index and age or parasitemia, respectively. Spearman rank correlation is presented as the best fit line and the coefficient ( $r$ ), as well as the  $p$ -values ( $p$ ), are shown for each age group. EBA-175: Erythrocyte binding antigen-175. MSP-1: Merozoite surface protein-1.



**Fig S3. No association between IgG anti-*Plasmodial* antibody levels and infection status. A)** Data presented in the scatterplots represent IgG antibody levels against different *P. falciparum* antigens (ME, SE, EBA-175 and MSP-1) by infection status, according to age group. **B)** scatterplots represent the parasite growth inhibition index of circulating antibody or parasite densities in the study population groups. Median levels were compared using nonparametric Kruskal–Wallis test for multiple comparisons and Wilcoxon signed-rank test for comparison between two groups. SE: Schizont extract. ME: Merozoite extract. EBA-175: Erythrocyte binding antigen-175. MSP-1: Merozoite surface protein-1. NI: Non-infected. AS: Asymptomatic. SY: Symptomatic. GI: Growth inhibition. OD: optical density. \*\* $p < 0.05$ .